COR · Q3 2025 Earnings
BullishCencora
Reported August 6, 2025
30-second summary
30-second take: Cencora delivered 8.7% revenue growth to $80.7B and adjusted EPS of $4.00 (+19.8% YoY), with U.S. Healthcare Solutions operating income up 29.1% on specialty strength and RCA contribution. Management raised and narrowed FY25 adjusted EPS guidance to $15.85–$16.00 and lifted U.S. segment operating income growth to 20–21%, while cutting the International segment OI outlook to a ~6% as-reported decline. The print is unambiguously bullish on U.S. specialty, with management explicitly templating International OI back to growth exiting Q4.
Headline numbers
EPS
Q3 FY2025
$4.00
Revenue
Q3 FY2025
$80.70B
+8.7% YoY
Gross margin
Q3 FY2025
3.6%
Operating margin
Q3 FY2025
1.1%
Key financials
Q3 FY2025| Metric | Q3 FY2025 | YoY |
|---|---|---|
| Revenue | $80.70B | +8.7% |
| EPS | $4.00 | — |
| Gross margin | 3.6% | — |
| Operating margin | 1.1% | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q3 FY2025| Segment | Q3 FY2025 | YoY |
|---|---|---|
| U.S. Healthcare Solutions | $72.9B | +8.5% |
| International Healthcare Solutions | $7.8B | +10.5% |
| U.S. Healthcare Solutions Operating Income Growth | 29.1% | — |
| International Healthcare Solutions Operating Income Change | -12.9% | — |
Other KPIs
Q3 FY2025| Segment | Q3 FY2025 |
|---|---|
| Adjusted Gross Profit Margin | 3.55% |
| Adjusted Operating Income Margin | 1.31% |
| Adjusted Diluted EPS Growth | 19.8% |
| Adjusted Operating Income Growth | 20.6% |
| FY2025 Adjusted Diluted EPS Guidance | $15.85–$16.00 |
| FY2025 Revenue Growth Guidance | ~9% |
Management tone
Management spoke from a position of unusual confidence for a distributor. Three things changed in this call's tone.
International went from a drag to a dated recovery. Last update framed International as a problem to be managed; this quarter management gave a specific inflection: "As we move into the fourth quarter, we have an easier comparison, and with continued sequential improvement from our global specialty logistics business, we expect to see the International Healthcare Solutions segment operating income return to growth exiting the fiscal year." They cut FY OI for the segment to ~-6% while simultaneously templating Q4 growth — a stark sequencing message that says "the pain is in the rearview."
Specialty stopped being a vertical and started being the identity. RCA is now described as a proof point — "Innovation is driving specialty pharmaceutical market growth, and [Cencora] is deepening our leadership in specialty" — not an acquisition to be integrated. Management's willingness to speak in detail about MFN policy engagement and MSO customer reception suggests they've crossed from defending the deal to leveraging it.
GLP-1 got quantified and de-risked. "In the quarter, GLP-1 sales increased $1.4 billion, or 19% year-over-year. Excluding sales of GLP-1s, our consolidated revenue growth would have been 8%." Management explicitly told UBS and Jefferies that GLP-1s are minimally profitable and won't expand margins in FY26. This is preemptive expectation management — getting ahead of the deceleration narrative before it hardens.
Confidence on long-term ranges hedged carefully. When pressed by UBS on the 2-year U.S. segment outperformance vs. 5–8% long-term OI growth and 8–12% EPS targets, management did not raise the long-term range. They acknowledged FY26 will face tougher comps (3 quarters of RCA in FY25 vs. 4 in FY26; 1 quarter of oncology customer loss vs. 4) and effectively signaled normalization. The bullish current-quarter tone is paired with a quiet reset on the trajectory.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Lisa Gill · JPMorgan
Asked about U.S. Healthcare segment revenue trim despite strong profit growth, and international business dynamics including SMID/mid-size biotech pharma environment and expected improvement as the year exits.
Management attributed U.S. revenue moderation to biosimilars (Part D and B), deceleration in GLP-1 growth (19% vs. prior year), and loss of a low-margin grocery customer. For international, explained subdued clinical trial activity pressuring specialty logistics and consulting; noted sequential growth in global specialty logistics in Q2 and expected Q3, with easier Q4 comps and return to operating income growth expected.
Elizabeth Anderson · Evercore ISI
Asked about RCA acquisition performance, customer feedback, and exposure of RCA and medical specialty segment to MFN policy changes.
Management expressed strong satisfaction with RCA integration, highlighting strong cultural fit and physician/practice leader appreciation. Noted market is adapting to MSO investments as evolution of support services. On MFN, stated it's too early to call outcomes, emphasized company engagement in Washington advocacy to maintain community provider access and ensure adequate reimbursement, particularly in Part B.
Michael Cheney · Learing Partners
Asked about moving pieces for fiscal 2026 guidance against 5-8% segment growth and 8-12% EPS growth targets, with Street expectations at 10% EPS growth; requested clarity on upside/downside sources.
Management deferred formal guidance to year-end planning but articulated key 2026 drivers: one additional quarter of RCA contribution, three quarters of customer loss impact (vs. one in FY25), utilization trends strength, specialty sales momentum, international growth recovery, and timing of capital deployment. Reiterated confidence in long-term guidance ranges.
Kevin Caliendo · UBS
Questioned why U.S. segment growth is significantly outperforming long-term guidance for nearly two years; asked if biosimilars or GLP-1 slowdown could normalize growth closer to 5-8% range.
Management stated GLP-1 slowdown wouldn't have major earnings impact due to minimal profitability; acknowledged not assuming same outperformance level going forward due to difficult comps against exceptional prior-year growth. Maintained confidence in long-term guidance but indicated expecting lower growth rates in near-term vs. recent past.
Jack Sebanon · Jeffreys
Asked what conditions need to occur for GLP-1 margins to expand over time as competition increases; whether margin expansion is possible or not achievable.
Management explained that GLP-1s are currently minimally profitable but could achieve normalized fee-for-service profitability as more competitors enter market; however, not anticipating margin expansion in FY26 planning timeframe, expecting them to remain minimally profitable.
What to watch into next quarter
Whether International Healthcare Solutions operating income actually prints positive YoY growth in Q4 as templated, or slips to "flat-to-down" and pushes the inflection to FY26.
Specialty logistics sequential OI in Q4 vs. Q3 — the third consecutive sequential improvement is the proof point management has staked the International recovery on.
Initial FY26 guide framing at the year-end print: whether U.S. OI growth lands inside the 5–8% long-term range or above it, given the RCA and oncology customer comp pressures management itemized.
GLP-1 quarterly growth rate trajectory — deceleration from 19% would erode the ex-GLP-1 vs. headline revenue gap; watch whether ex-GLP-1 growth holds at ~8%.
Any FY26 commentary on biosimilar mix headwind to U.S. revenue alongside operating income tailwind — the divergence in this quarter (revenue trimmed, OI raised hard) is the model investors need calibrated.
Sources
- Cencora Q3 FY2025 press release (Exhibit 99.1, filed 2025-08-06): https://www.sec.gov/Archives/edgar/data/1140859/000114085925000119/exhibit991-q32025.htm
- Cencora Q3 FY2025 earnings call commentary (Q&A and prepared remarks, as extracted)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.